Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study

Trial Profile

Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Immunoglobulin G (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Therapeutic Use
  • Acronyms IDIDM
  • Most Recent Events

    • 10 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
    • 10 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 04 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top